One UPR, the pro-angiogenic factor VEGFA, was activated by CPA treatment in GL261 tumors but was uniquely inhibited in LLC tumors, as was validated by analysis of CPA effects on LLC tumor microvessel density. This evidence concerns the gene VEGFA and neoplasm.